Grand Pharmaceutical Group (SEHK:512) - Cotización, noticias y análisis

Resumen de acción 512

Grand Pharmaceutical Group Limited, holding de inversiones, se dedica a la investigación y desarrollo, fabricación y venta de preparados farmacéuticos y dispositivos médicos, productos biotecnológicos y sanitarios y materias primas farmacéuticas.

Acerca de la empresa

512 fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	3/6
Past Performance	2/6
Financial Health	6/6
Dividends	2/6

Recompensas

Cotiza un 75.3% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 19.99%

Análisis de riesgos

Historial de dividendos inestable

Competidores de Grand Pharmaceutical Group Limited

SSY Group

SEHK:2005

HK$14.2b

Simcere Pharmaceutical Group

SEHK:2096

HK$14.6b

United Laboratories International Holdings

SEHK:3933

HK$17.4b

SciClone Pharmaceuticals (Holdings)

SEHK:6600

HK$11.0b

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Grand Pharmaceutical Group
Historical stock prices
Current Share Price	HK$4.54
52 Week High	HK$5.40
52 Week Low	HK$3.17
Beta	0.69
1 Month Change	11.55%
3 Month Change	36.34%
1 Year Change	-14.98%
3 Year Change	-31.21%
5 Year Change	1.11%
Change since IPO	-82.54%

Noticias y actualizaciones recientes

Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

Apr 25

Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

Mar 25

Recent updates

Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

Apr 25

Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

Mar 25

If You Like EPS Growth Then Check Out Grand Pharmaceutical Group (HKG:512) Before It's Too Late

Jan 24

These 4 Measures Indicate That Grand Pharmaceutical Group (HKG:512) Is Using Debt Safely

Dec 13

Grand Pharmaceutical Group Limited's (HKG:512) Intrinsic Value Is Potentially 45% Above Its Share Price

Nov 27

With EPS Growth And More, China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Is Interesting

Oct 25

China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Seems To Use Debt Rather Sparingly

Sep 01

Do China Grand Pharmaceutical and Healthcare Holdings's (HKG:512) Earnings Warrant Your Attention?

Jul 12

We Think China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Can Stay On Top Of Its Debt

Apr 26

Calculating The Fair Value Of China Grand Pharmaceutical and Healthcare Holdings Limited (HKG:512)

Apr 08

Here's Why We Think China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Is Well Worth Watching

Mar 24

If You Had Bought China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Shares Five Years Ago You'd Have Earned 332% Returns

Mar 11

Are Robust Financials Driving The Recent Rally In China Grand Pharmaceutical and Healthcare Holdings Limited's (HKG:512) Stock?

Feb 22

China Grand Pharmaceutical and Healthcare Holdings's (HKG:512) Earnings Are Growing But Is There More To The Story?

Jan 21

Rentabilidad de los accionistas

	512	HK Pharmaceuticals	Mercado HK
7D	5.1%	4.5%	2.8%
1Y	-15.0%	-14.1%	-8.1%

Rentabilidad vs. Industria: 512 igualó a la industria Hong Kong Pharmaceuticals, que obtuvo un rendimiento del -14.1% el año pasado.

Rentabilidad vs. Mercado: 512 obtuvo unos resultados inferiores a los del mercado Hong Kong, que fue del -10.1% el año pasado.

Volatilidad de los precios

Is 512's price volatile compared to industry and market?
512 volatility
512 Average Weekly Movement	5.5%
Pharmaceuticals Industry Average Movement	6.2%
Market Average Movement	7.5%
10% most volatile stocks in HK Market	14.9%
10% least volatile stocks in HK Market	3.6%

Precio estable de las acciones: El precio de las acciones de 512 ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de 512 (6%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1995	10,534	Chao Zhou	www.grandpharm.com

Grand Pharmaceutical Group Limited, un holding de inversiones, se dedica a la investigación y desarrollo, fabricación y venta de preparados farmacéuticos y dispositivos médicos, productos biotecnológicos y sanitarios y materias primas farmacéuticas. La empresa ofrece productos relacionados con el aparato respiratorio, la oftalmología, las urgencias cerebrovasculares y la biotecnología. Fabrica y vende productos farmacéuticos, taurina, agroquímicos, medicina química y aminoácidos.

Resumen de fundamentos de Grand Pharmaceutical Group Limited

¿Cómo se comparan los beneficios e ingresos de Grand Pharmaceutical Group con su capitalización de mercado?
Estadísticas fundamentales de 512
Capitalización bursátil	HK$15.90b
Beneficios(TTM)	HK$1.88b
Ingresos (TTM)	HK$10.53b

8.5x

Ratio precio-beneficio (PE)

1.5x

Ratio precio-ventas (PS)

¿Está 512 sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de 512
Ingresos	HK$10.53b
Coste de los ingresos	HK$4.01b
Beneficio bruto	HK$6.52b
Otros gastos	HK$4.64b
Beneficios	HK$1.88b

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	0.54
Margen bruto	61.96%
Margen de beneficio neto	17.85%
Ratio deuda/patrimonio	21.8%

¿Cómo se ha desempeñado 512 a largo plazo?

Ver rendimiento histórico y comparativa

Dividendos

5.7%

Rentabilidad actual por dividendo

49%

Ratio de pagos

¿Paga 512 dividendos fiables?

Ver historial de dividendos e índices de referencia de 512

¿Cuándo hay que comprar 512 para recibir un próximo dividendo?
fechas de dividendos de Grand Pharmaceutical Group
Fecha ex dividendo	Jun 06 2024
Fecha de pago de dividendos	Jun 27 2024
Días hasta ex dividendo	33 days
Días hasta la fecha de pago de dividendos	54 days

¿Paga 512 dividendos fiables?

Ver historial de dividendos e índices de referencia de 512

Resumen de acción 512

Recompensas

Análisis de riesgos

Competidores de Grand Pharmaceutical Group Limited

SEHK:2005

HK$14.2b

SEHK:2096

HK$14.6b

SEHK:3933

HK$17.4b

SEHK:6600

HK$11.0b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Grand Pharmaceutical Group Limited, Annual General Meeting, Jun 04, 2024

Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

Executive Chairman recently bought HK$371k worth of stock

Executive Chairman recently bought HK$243k worth of stock

Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

Dividend increased to HK$0.26

Recent updates

Grand Pharmaceutical Group Limited, Annual General Meeting, Jun 04, 2024

Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

Executive Chairman recently bought HK$371k worth of stock

Executive Chairman recently bought HK$243k worth of stock

Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

Dividend increased to HK$0.26

Executive Chairman recently bought HK$381k worth of stock

Grand Pharmaceutical Group Limited Proposes Ordinary Final Cash Dividend for the Year Ended 31 December 2023, Payable on 27 June 2024

Full year 2023 earnings: EPS misses analyst expectations

Grand Pharmaceutical Group Limited Proposes Dividend for the Year Ended 31 December 2023, Payable on 27 June 2024

Grand Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 19, 2024

Grand Pharmaceutical Group Limited Announces Update on Global Innovative Ophthalmic Drug GPN00884

Grand Pharmaceutical Group Limited Announces the Investigational New Drug Application in China of the Group's Global Innovative Ophthalmic Drug GPN00884 Was Accepted by NMPA

Grand Pharmaceutical Group Limited Announces the Investigational New Drug Application of ARC01 (A002)

Grand Pharmaceutical Group Limited Announces Phase III Clinical Trial in China of the Groups Global Innovative Ophthalmic Drug GPN00833 Has Completed the First Patient Enrollment and Dosing

We Think Grand Pharmaceutical Group (HKG:512) Can Stay On Top Of Its Debt

Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching

Grand Pharmaceutical Group Limited Announces Phase III Clinical Study in China of the Group's Global Innovation Drug RYaltris® Compound Nasal Spray Has Completed and Successfully Met Primary Endpoint

Grand Pharmaceutical Group Limited Announces That the Phase I Clinical Trial of Apad, A Global Innovative Drug Independently Developed by the Group for the Treatment of Sepsis, Has Completed First Subject Enrollment and Dosing Approved Recently

First half 2023 earnings released: EPS: HK$0.29 (vs HK$0.20 in 1H 2022)

Grand Pharmaceutical Group Limited Announces New Mra Drug of the Group Eplerenone Tablets Was Granted Drug Registration Certificate

Grand Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 10, 2023

Grand Pharmaceutical Group Limited Announces Approval by National Medical Products Administration to Conduct Phase II Clinical Study in China

Less than half of directors are independent

Grand Pharmaceutical Group Limited Appoints Yang Guang as an Executive Director

Grand Pharmaceutical Group Limited Announces Resignation of Niu Zhanqi as Executive Director

Less than half of directors are independent

Grand Pharmaceutical Group's (HKG:512) Dividend Will Be Increased To HK$0.14

Grand Pharmaceutical Group Limited Announces Board Changes

Upcoming dividend of HK$0.14 per share at 2.9% yield

Grand Pharmaceutical Group Limited Announces the Multicenter Phase III Clinical Trial of Ryaltris Compound Nasal Spray

Is Grand Pharmaceutical Group (HKG:512) A Risky Investment?

Full year 2022 earnings released: EPS: HK$0.59 (vs HK$0.68 in FY 2021)

National Medical Products Administration of the People's Republic of China Accepts Grand Pharmaceutical Group Limited's Investigational New Drug Applications of the Group Three Innovative Products in China

Grand Pharmaceutical Group Limited Conducts Clinical Trials of its Innovative Oral Small Molecule 3Cl Protease Inhibitor GS221 Against COVID-19

Investor sentiment improved over the past week

Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly

Less than half of directors are independent

Investor sentiment improved over the past week

Grand Pharmaceutical Group Limited Announces NMPA Approves Clinical Trial Application in China for Global Innovative Radionuclide-Drug Conjugate TLX591-CDx

Grand Pharmaceutical Group Limited Announces Clinical Trial Application in China for Global Innovative Radionuclide-Drug Conjugate TLX250-CDX Approved by NMPA

Is Grand Pharmaceutical Group Limited (HKG:512) Trading At A 43% Discount?

Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly

First half 2022 earnings released

Grand Pharmaceutical Group Limited Provides Unaudited Earnings Guidance for Six Months Ended 30 June 2022

Grand Pharmaceutical Group Announces Clinical Trial Applications in China for Global Innovative Radionuclide-Drug Conjugates TLX591-CDX AND TLX250-CDX Accepted by NMPA

Grand Pharmaceutical Group Limited to Report First Half, 2022 Results on Aug 10, 2022

Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching

Executive Director recently bought HK$535k worth of stock

Upcoming dividend of HK$0.11 per share

Grand Pharmaceutical Group's (HKG:512) Dividend Will Be HK$0.11

Grand Pharmaceutical Group Limited Declares Final Dividend for the Year Ended 31 December 2021

Full year 2021 earnings released: EPS: HK$0.68 (vs HK$0.52 in FY 2020)

Less than half of directors are independent

Is Grand Pharmaceutical Group Limited (HKG:512) Trading At A 45% Discount?

Grand Pharmaceutical Group Limited Announces Phase III Clinical Trial of Global Innovative Drug Ryaltris Compound Nasal Spray Successfully Completed the First Patient Enrollment in China

Grand Pharmaceutical Group (HKG:512) Has A Rock Solid Balance Sheet

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Now 21% undervalued after recent price drop